FROM:
Business Wire
January 20, 2004 Tuesday
HEADLINE: Neural Stem Cells Have Tremendous Therapeutic Potential in the
Aging
Brain
DATELINE: LARCHMONT, N.Y., Jan. 20, 2004
Neural stem cells hold the key to innovative new treatments for
age-associated degeneration and traumatic injury to the brain and spinal
cord,
according to a series of cutting-edge reports and critical reviews in the
December 2003 special issue of Journal of Hematotherapy & Stem Cell
Research
(Volume 12, Number 6), a peer-reviewed journal published by Mary Ann
Liebert,
Inc. (www.liebertpub.com). The entire issue is available free online at
www.liebertpub.com/jht.
"Neural stem cell research is revolutionizing ways by which we could
target
and treat intractable and devastating neurological diseases such as Lou
Gehrig
's, Parkinson's, and Alzheimer's diseases, as well as trauma to the brain
or
spinal cord," says Marc A. Williams, Ph.D., Co-Editor of the Journal and
Research Associate in the Department of Neurology at The Johns Hopkins
University School of Medicine.
The issue includes a critical report by Su-Chun Zhang, Ph.D. of the
WiCell
Institute that describes methods for guiding human embryonic stem cells
to
become neural cells and for reprogramming those cells so that they will
not be
recognized and destroyed by the immune system. A key paper by Tobi L.
Limke,
Ph.D., and Mahendra S. Rao, Ph.D., of the National Institutes of Health,
discusses the important but poorly understood concept of the brain's
diminished
capacity to generate new neurons as it ages. Age-associated
neurodegenerative
diseases worsen the phenomenon of neuron loss as the brain ages, and the
authors
describe the pitfalls and possibilities for neural stem cell therapy in
the
aging brain.
Journal of Hematotherapy & Stem Cell Research, edited by Denis
English,
Ph.D., Director, Experimental Cell Research Program, The Methodist
Research
Institute, and Professor of Medicine at the Indiana University School of
Medicine in Indianapolis, is an authoritative peer-reviewed journal
published
bimonthly in print and online. The journal is dedicated to communication
and
objective analysis of developments in the biology, characteristics, and
therapeutic utility of stem cells, especially those of the hematopoietic
system.
A complete table of contents and free sample issue may be viewed online
at
www.liebertpub.com/jht.
Mary Ann Liebert, Inc., is a privately held, fully integrated media
company
known for establishing authoritative peer-reviewed journals in many
promising
areas of science and biomedical research, including Cloning and Stem
Cells,
Human Gene Therapy, and Tissue Engineering. Its biotechnology trade
magazine,
Genetic Engineering News (GEN), was the first in its field and is today
the
industry's most widely read publication worldwide. A complete list of the
firm's
60 journals, books, and trade publications is available at
www.liebertpub.com.
CONTACT: Mary Ann Liebert, Inc., Larchmont
Vicki Cohn, 914-834-3100, ext. 617
[log in to unmask]
URL: http://www.businesswire.com
LOAD-DATE: January 21, 2004
----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn
